Matan Companies Breaks Ground on Progress Labs At Riverside I in Frederick

Published on :

Matan Companies has broken ground on the third of its six Progress Labs developments along the I-270 corridor, Progress Labs at Riverside I in Frederick, Maryland. The speculative project, slated to deliver in the Fall of 2022, will total 215,000 square feet comprised of a single story 118,000 square foot biomanufacturing building, along with a three story 96,000 square foot support building to accommodate additional manufacturing, lab, quality control, administration, and support space. The facility will bring in excess of 1,000 new life science jobs to Frederick.

Regional Collaborations Emerge to Address the Biomanufacturing Workforce Crisis

Published on :

We have been covering the biomanufacturing workforce at length this year because it remains one of the most important topics for companies in today’s near full-employment job market.

Maryland Showcases Life Sciences Ecosystem at BIODigital 2021

Published on :

When the Biotechnology Innovation Organization (BIO) convenes its annual trade show this month, Maryland’s life sciences ecosystem, which played a significant role in combating the global COVID-19 pandemic, will be on full display.

Frederick Biotech Leaders Discuss Strategies for Talent Recruitment and Retention

Published on :

Maryland’s reputation as the destination state for biotech jobs and life science research continues to climb as new startups emerge across its biohealth cluster regions.

BioFactura Announces Initiation of Phase I Study of BFI-751, a Stelara® (ustekinumab) Biosimilar

Published on :

BioFactura, a leading developer of high-value biosimilar and biodefense drugs using its patented StableFastTM platform, announces today the initiation of a pivotal PK (pharmacokinetics) Phase 1 Clinical Trial for its Ustekinumab Biosimilar (BFI-751), to assess the effects on healthy human volunteers compared to the biologic medicine, Stelera®. This is the first time BFI-751 has been administered to humans, as authorized by the Ethics Committees in both Australia and New Zealand.

Frederick’s RoosterBio Releases RoosterGEM™, Cell and Gene Therapy’s First Complete Transduction Medium

Published on :

RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems for cell and gene therapy product developers, today announced the launch of its product RoosterGEM™, a stand-alone, complete gene transfer medium that is optimized to remove key challenges in primary cell genetic modification. RoosterGEM, abbreviated for Rooster Genetic Engineering Medium, complements RoosterBio’s hMSC cell engineering system to offer a new and streamlined path for discovery, preclinical, and applied product development research – faster than ever before.

Matan Companies to Deliver 215,000 Square Feet at Frederick’s Riverside Research Park

Published on :

Matan Companies announces today leasing has begun at Progress Labs at Riverside I in Frederick, Maryland. Receiving its site plan approval on March 9, the 215,000 square feet of biomanufacturing-ready space will include a 96,000 square foot existing building as well as a 119,000 square foot expansion building, which is slated to break ground in May 2021 and is expected to be fully complete by Spring 2022.

Attracting Talent in Frederick’s Booming Biotech Industry

Published on :

In the BioHealth Capital Region, where reports are stating there are 2,000 current and projected open jobs within the biotech sector, the topic of attracting and retaining talent has never been more urgent. Some companies will adapt and succeed, while others will struggle to keep up. We want to help you and your company understand the challenges, take advantage of the opportunities, and succeed in growing your business, and the biotech community, in the BioHealth Capital Region.

Matan Signs Deal with Ellume for Two Full Buildings at Progress Labs at Center 85

Published on :

Matan Companies announced today the signing of a long-term lease with Ellume, an Australian-based company that develops diagnostic solutions for infectious diseases. The Frederick facility, totaling over 180,000 square feet in two full buildings at Progress Labs at Center 85, will be Ellume’s first in the United States and will produce diagnostic tests for infectious diseases, including at-home rapid tests for COVID-19.